Rentschler Biopharma SE, a global contract development and manufacturing organization for biopharmaceuticals, has appointed
Martin Kessler as CEO of Rentschler Biopharma Inc., the company’s wholly owned U.S. subsidiary, and as senior vice president transformation of Rentschler Biopharma SE.
Kessler brings more than 15 years of experience in pharmaceutical and biopharmaceutical operations and strategy. At Rentschler Biopharma, he will drive the transformation throughout the company as it grows strategically into new fields and technologies. In his role as head of the U.S. business, he will lead the ongoing expansion at the company’s Greater Boston area site, which includes expanding capabilities, capacity and talent.